Journey Medical Corp (DERM) stock

DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% below fair value

$4.33−0.06 (-1.37%)

Close on Nov 13, 2026Market cap $122.21MP/E –Yield –

Journey Medical ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Journey Medical's ebitda for the twelve months ending Dec 31, 2020 was $7.86M. For fiscal 2021 it was -$34.88M, down 544.0% from the year before.

Period	Period end	Value	Change
FY2021	Dec 31, 2021	-$34.88M	-544.0%
FY2020	Dec 31, 2020	$7.86M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q4 FY2020	Dec 31, 2020	$3.63M	–

Parsed from the XBRL in Journey Medical's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is DERM.

Revenue growth17.0% · median -4.0%

Gross margin65.9% · median 64.0%

Operating margin-2.9% · median -14.4%

Net margin-7.3% · median -12.7%

Advertisement
300 × 250

See a number that looks wrong?